Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol.
OBJECTIVES: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran.
METHODS: This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Exposure-adjusted incidence rates and Kaplan-Meier estimates of cumulative incidence of reported treatment-emergent adverse events (TEAE), abnormal laboratory measurements, and incidence of antidrug antibodies were analyzed.
RESULTS: This analysis included 3,576 patients treated with inclisiran for up to 6 years and 1,968 patients treated with placebo for up to 1.5 years, with 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. Kaplan-Meier analyses showed that TEAEs that were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs.
CONCLUSIONS: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia.
| Errataetall: |
CommentIn: J Am Coll Cardiol. 2023 Dec 12;82(24):2262-2264. - PMID 38057067 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 82(2023), 24 vom: 12. Dez., Seite 2251-2261 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wright, R Scott [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALN-PCS |
|---|
| Anmerkungen: |
Date Completed 11.12.2023 Date Revised 08.02.2024 published: Print CommentIn: J Am Coll Cardiol. 2023 Dec 12;82(24):2262-2264. - PMID 38057067 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacc.2023.10.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365479748 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365479748 | ||
| 003 | DE-627 | ||
| 005 | 20240208231939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2023.10.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM365479748 | ||
| 035 | |a (NLM)38057066 | ||
| 035 | |a (PII)S0735-1097(23)07739-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wright, R Scott |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2023 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Am Coll Cardiol. 2023 Dec 12;82(24):2262-2264. - PMID 38057067 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Inclisiran is a small interfering RNA agent to lower low-density lipoprotein cholesterol | ||
| 520 | |a OBJECTIVES: The purpose of this study was to provide reliable evidence to date on the long-term safety profile of inclisiran | ||
| 520 | |a METHODS: This post hoc analysis comprised patients treated with 300 mg inclisiran sodium or placebo in the completed (ORION-1, -3, -5, -9, -10, and -11) and ongoing (ORION-8) trials. Exposure-adjusted incidence rates and Kaplan-Meier estimates of cumulative incidence of reported treatment-emergent adverse events (TEAE), abnormal laboratory measurements, and incidence of antidrug antibodies were analyzed | ||
| 520 | |a RESULTS: This analysis included 3,576 patients treated with inclisiran for up to 6 years and 1,968 patients treated with placebo for up to 1.5 years, with 9,982.1 and 2,647.7 patient-years of exposure, respectively. Baseline characteristics were balanced between groups. Kaplan-Meier analyses showed that TEAEs that were serious or led to discontinuation; hepatic, muscle, and kidney events; incident diabetes; and elevations of creatine kinase or creatinine accrued at a comparable rate between groups for up to 1.5 years, with similar trends continuing for inclisiran beyond this period. Numerically fewer major cardiovascular events reported as TEAEs occurred with inclisiran during this period. Treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these persistent (1.4%) and not associated with greater incidence of TEAEs leading to study drug discontinuation or serious TEAEs | ||
| 520 | |a CONCLUSIONS: Long-term treatment with inclisiran was well tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ASCVD | |
| 650 | 4 | |a LDL-C | |
| 650 | 4 | |a PCSK9 | |
| 650 | 4 | |a inclisiran | |
| 650 | 4 | |a long-term safety | |
| 650 | 7 | |a ALN-PCS |2 NLM | |
| 650 | 7 | |a Cholesterol, LDL |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a Anticholesteremic Agents |2 NLM | |
| 650 | 7 | |a Proprotein Convertase 9 |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 700 | 1 | |a Koenig, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Landmesser, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Leiter, Lawrence A |e verfasserin |4 aut | |
| 700 | 1 | |a Raal, Frederick J |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Gregory G |e verfasserin |4 aut | |
| 700 | 1 | |a Lesogor, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Maheux, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Stratz, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Zang, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Kausik K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 82(2023), 24 vom: 12. Dez., Seite 2251-2261 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2023 |g number:24 |g day:12 |g month:12 |g pages:2251-2261 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2023.10.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2023 |e 24 |b 12 |c 12 |h 2251-2261 | ||